KLDO (Kaleido Biosciences) Current Accrued Expense: $4.62 Mil (As of Dec. 2021)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Kaleido Biosciences Current Accrued Expense?

Kaleido Biosciences KLDO Current Accrued Expense is $4.62 Mil as of Dec. 2021.

Kaleido Biosciences's Current Accrued Expense for the quarter that ended in Dec. 2021 was $4.62 Mil.

Kaleido Biosciences's quarterly Current Accrued Expense increased from Jun. 2021 ($3.13 Mil) to Sep. 2021 ($5.97 Mil) but then declined from Sep. 2021 ($5.97 Mil) to Dec. 2021 ($4.62 Mil).

Kaleido Biosciences's annual Current Accrued Expense declined from Dec. 2019 ($4.66 Mil) to Dec. 2020 ($4.23 Mil) but then increased from Dec. 2020 ($4.23 Mil) to Dec. 2021 ($4.62 Mil).

Kaleido Biosciences Current Accrued Expense Related Terms

Kaleido Biosciences Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Kaleido Biosciences's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kaleido Biosciences Current Accrued Expense Chart

Kaleido Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Current Accrued Expense
Get a 7-Day Free Trial 1.96 4.11 4.66 4.23 4.62

Kaleido Biosciences Quarterly Data
Sep17 Dec17 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.23 3.39 3.13 5.97 4.62

Kaleido Biosciences Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $4.62 Mil mean?
Kaleido Biosciences (KLDO) has a Current Accrued Expense of $4.62 Mil as of Dec. 2021. Current Accrued Expense records the total amount of accrued expenses. View historical data on Kaleido Biosciences and its competitors.
Is Kaleido Biosciences' Current Accrued Expense too high?
Kaleido Biosciences' current Current Accrued Expense is $4.62 Mil.
How does Kaleido Biosciences' Current Accrued Expense compare to NPTX and GSTC?
Kaleido Biosciences' Current Accrued Expense of $4.62 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Kaleido Biosciences and its competitors. Kaleido Biosciences's current Current Accrued Expense is $4.62 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kaleido Biosciences stock overvalued right now?
Kaleido Biosciences (KLDO) has a current Current Accrued Expense of $4.62 Mil. The current Current Accrued Expense is $4.62 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Kaleido Biosciences (KLDO), the current Current Accrued Expense is $4.62 Mil as of Dec. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kaleido Biosciences Business Description

Address 65 Hayden Avenue, Lexington, MA, USA, 02421
Kaleido Biosciences Inc is a clinical-stage healthcare company. It is focused on leveraging the potential of the microbiome organ to treat disease and improve human health. Its product candidates are Microbiome Metabolic Therapies, or MMTs, which are designed to modulate the metabolic output and profile of the microbiome.